Cassava Sciences Announces Expansion Of Open-Label Extension Trials By Up To An Additional 36 Months To Provide Participants The Opportunity To Continue On Treatment, If They Desire, Pending Results Of The Ongoing Phase 3 Trials
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences (NASDAQ:SAVA) announced an extension of its open-label extension trials for simufilam in Alzheimer's disease by up to 36 months. This allows participants to continue treatment pending the results of ongoing Phase 3 trials. The company will also add cognition and plasma biomarker monitoring to gather additional long-term data.
July 30, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cassava Sciences announced an extension of its open-label extension trials for simufilam in Alzheimer's disease by up to 36 months. This allows participants to continue treatment pending the results of ongoing Phase 3 trials. The company will also add cognition and plasma biomarker monitoring to gather additional long-term data.
The extension of the open-label trials and the addition of cognition and plasma biomarker monitoring are positive developments for Cassava Sciences. These steps indicate the company's commitment to gathering comprehensive long-term data, which could support the efficacy and safety profile of simufilam. This news is likely to be viewed favorably by investors, potentially leading to a short-term increase in SAVA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100